FATE THERAPEUTICS INC
About FATE THERAPEUTICS INC
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $6.6M
- Net income
- -$136.3M
- Total assets
- $318.9M
- Market cap
- $230.8M
- Operating margin
- -2222.4%
- Net margin
- -2051.1%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $6.6M
- Operating expenses
- $154.3M
- Operating income
- -$147.7M
- Income tax
- $2.0K
- Net income
- -$136.3M
- EPS (basic)
- $-1.15
- EPS (diluted)
- $-1.15
Balance sheet
- Total assets
- $318.9M
- Current assets
- $208.7M
- Total liabilities
- $111.8M
- Current liabilities
- $36.1M
- Shareholders’ equity
- $207.2M
Cash flow
- Operating cash flow
- -$106.1M
- Investing cash flow
- $111.2M
- Financing cash flow
- $5.5M
- Net cash flow
- $10.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $230.8M
- EPS (diluted)
- $-1.15
- Shares outstanding
- 120.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 1, 2013
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $136.3M in FY2025.
- Revenue declined 88% from FY2021 to FY2025.
- Trading 33% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review FATE THERAPEUTICS INC.
Write a review
News about FATE THERAPEUTICS INC
News & sentiment via Polygon.io
